HPV DNA microarray
A new microarray based on state-of-the-art EUROArray technology provides fast and reliable detection and typing of human papillomavirus (HPV). HPV is involved in the development of cervical carcinoma, and HPV testing plays a central role in risk assessment and early diagnosis of this cancer. In contrast to Pap examinations, HPV detection is not dependent on subjective evaluation and it offers very high sensitivity even in the early stages of infection. The HPV EUROArray is based on detection of the viral oncogenes E6/E7, which provides highest possible sensitivity. Using an extensive panel of specific primers and probes, the EUROArray detects all 30 genitally relevant HPV subtypes in one test and distinguishes between high-risk subtypes that trigger cancer and low-risk subtypes that cause benign genital warts. Multiple infections are reliably identified, and primary and persistent infections can be differentiated. A positive high-risk result indicates an increased risk for cervical carcinoma, which can then be minimized by more frequent follow-up examinations to detect morphological cell changes at an early stage. Based on the recommendations of the respective professional societies, HPV-negative women can forgo Pap smears for a longer time interval. The EUROArray procedure is extremely easy to perform, requiring no expertise in molecular biology. DNA from patient samples is first amplified by multiplex polymerase chain reaction (PCR). The PCR products are then incubated with Biochip microarray slides containing immobilized complementary DNA probes. Results are evaluated and interpreted fully automatically by the user-friendly EUROArrayScan software. Meticulously designed primers, ready-to-use PCR components and integrated controls all contribute to the reliability of the analysis. The entire EUROArray process from sample arrival to report release is IVD validated and CE registered.
